Iloprost (Ventavis)

An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.

Also Known As:

Networked: 854 relevant articles (148 outcomes, 166 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Seeger, Werner: 16 articles (03/2015 - 01/2002)
2.	Grimminger, Friedrich: 11 articles (07/2008 - 01/2002)
3.	Weissmann, Norbert: 10 articles (07/2008 - 04/2002)
4.	Ghofrani, Hossein Ardeschir: 9 articles (05/2010 - 04/2002)
5.	Seeger, W: 9 articles (01/2006 - 03/2000)
6.	Olschewski, Horst: 8 articles (05/2010 - 01/2002)
7.	Olschewski, H: 8 articles (03/2009 - 03/2000)
8.	Schermuly, Ralph Theo: 8 articles (07/2008 - 04/2002)
9.	Grimminger, F: 8 articles (01/2006 - 03/2000)
10.	Ghofrani, H A: 8 articles (01/2006 - 03/2000)

Related Diseases

1.	Pulmonary Hypertension (Ayerza Syndrome) 03/01/2008 - "In a randomized, double-blind, placebo controlled, multicenter study in 203 patients with pulmonary hypertension inhaled iloprost showed significant improvement of exercise capacity and pulmonary hemodynamics with excellent tolerability and safety. " 06/01/2013 - "Inhaled NO and iloprost significantly reduced pulmonary hypertension and contributed to the improvement in right ventricular function. " 01/01/2004 - "Inhaled iloprost 2.5 or 5 microg six or nine times daily for 12 weeks (n = 101) significantly (p < 0.01) improved a combined clinical endpoint of a > or =10% increase in distance walked in 6 minutes and an improvement of > or =1 class in New York Heart Association functional class without clinical deterioration or death (16.8 versus 4.9% of placebo recipients, n = 102) in patients with severe PPH or selected forms of nonprimary pulmonary hypertension. " 01/01/2008 - "In animals with acute pulmonary hypertension, inhaled iloprost improved global haemodynamics primarily via selective pulmonary vasodilatation and restoration of left ventricular preload. " 02/01/2004 - "The main objective of the present study was to evaluate the safety and efficacy of inhaled iloprost in HIV-related pulmonary hypertension. "
2.	Ischemia 03/01/2002 - "Iloprost given in a standard dose regimen (0.5-2 ng/kg/min for 6 hours daily over 21-28 days) has proven to be effective and safe in hospitalized patients with critical limb ischemia. " 09/01/2006 - "Recently, iloprost has been shown to be safe and effective in critical limb ischemia patients when administered per 7 days. " 11/01/2008 - "Iloprost infusion for 72 hr after open AAA repair was associated with improved systemic perfusion and decreased systemic ischemia. " 04/01/1996 - "Iloprost (12 nm/l) inhibited the release of TXA2 and improved the recovery of cardiac hemodynamics after ischemia. " 10/01/2015 - "In this study, we aimed to investigate the effects of 1 week infusion of iloprost in the treatment of patients with chronic limb ischemia. "
3.	Ulcer 09/01/2008 - "Low-dose iloprost was shown to be equally effective as high-dose iloprost in longterm treatment and was very effective in therapy of digital ulcers. " 09/01/2003 - "In three different studies, iloprost given for 5 days in the highest tolerated dose of 1-2 ng/kg/min provided a significant improvement of the disease measured by the number and intensity of Raynaud attacks, healing of digital ulcers, and digital perfusion. " 01/01/1994 - "This study failed to show any statistically significant reduction in the ulcer size as a result of the iloprost treatment compared to the placebo treatment. " 03/15/2007 - "g., iloprost, can be recommended as first-line treatment of ischemic digital ulcers. " 01/01/2000 - "Intravenous Iloprost is effective in the treatment of Raynaud's phenomenon secondary to scleroderma at decreasing the frequency and severity of attacks and preventing or healing digital ulcers. "
4.	Reperfusion Injury 01/01/2014 - "These results indicate that administration of iloprost may have protective effects against ischemia reperfusion injury (Fig. " 05/01/2014 - "Our results support the hypothesis that iloprost enhances protection against cardiac ischemia reperfusion injury. " 07/01/2003 - "We demonstrated in an isolated lung perfusion model that iloprost ameliorates post-ischemic lung reperfusion injury and maintains an appropriate pulmonary ET-1 balance." 07/01/2003 - "Iloprost ameliorates post-ischemic lung reperfusion injury and maintains an appropriate pulmonary ET-1 balance." 03/01/2014 - "The aim of this study was to investigate the effects of iloprost (IL) on ischemia-reperfusion injury in a rodent model. "
5.	Pain (Aches) 01/01/2008 - "We found a significant improvement in pain, functional and radiological outcome in BME and early AVN stages after iloprost application, whereas patients with advanced AVN stages did not benefit from iloprost infusions. " 10/01/1991 - "Thus, a 2-week iloprost infusion was shown to be safe and effective as a treatment for ischaemic rest pain caused by PAOD." 05/01/2011 - "However, the results of this case series confirm previous findings that in early stages of insufficient osseous blood flow iloprost can contribute to the relief of pain and improve joint function." 08/01/2009 - "Our current data confirm the findings of other investigators that healing of advanced stages of AVN is not possible, but that in early stages of AVN, pain relief and an improvement of joint function can be achieved by iloprost." 01/01/2008 - "In addition to other drugs, iloprost may be an alternative substance which should be considered in the treatment of BME/AVN-associated pain."

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Alprostadil (Muse)
3.	Prostaglandins
4.	Idiopathic pulmonary hypertension
5.	sildenafil (Viagra)
6.	bosentan (Tracleer)
7.	Nitric Oxide (Nitrogen Monoxide)
8.	Oxygen
9.	Dinoprostone (PGE2)
10.	Diltiazem (Cardizem)

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Amputation
3.	Cardiopulmonary Bypass (Heart-Lung Bypass)
4.	Decompression
5.	Heart Transplantation (Grafting, Heart)